Michael Schickler, Ph.D., Chief Executive Officer
Dr. Schickler brings over 18 years of profound managerial and technological experience in the biopharmaceutical industry. Dr. Schickler has been the CEO of CureTech Ltd. since May 2001 and played a key role in transforming it from a virtual, university-based, entity into an independent company. Until recently, he also served as Managing Director of Clal Life Sciences L.P., the research center of Clal Biotechnology Industries in Israel which he also helped to establish. Prior thereto, Dr. Schickler held various managerial positions with Pharmos Corporation and was involved in the development of several of Pharmos’s drugs. Prior to joining Pharmos, Dr. Schickler held an academic position with the Volcani Institute, Israel and research position with Hoffmann-La Roche Inc., US. Dr. Schickler earned his Ph.D. from the Weizmann Institute of Science in Israel, has M.Sc. magna cum laude in immunology from Tel-Aviv University, Israel and holds a diploma in business administration from Lincoln University, UK.

Rinat Rotem-Yehudar, Ph.D., Vice President, Research & Development
Dr. Rotem-Yehudar has been with CureTech since 2003 and has extensive research experience in the fields of molecular immunology and biochemistry. Prior to becoming the company’s Head of Research she was working as senior scientist leading the molecular and cellular immunology research at the company. Prior thereto, Dr. Rotem-Yehudar was with Trojanix, a start up biotechnology project focused on drug delivery platform which she co-founded with Prof. Rachel Ehrlich at the Tel-Aviv University. Dr. Rotem-Yehudar gained extensive post-doctoral training working with Prof. Mia Horowitz at Tel-Aviv University, Israel, on the molecular and biochemical aspects relating to the activity of EDH1 protein, a key regulator of endocytosis modulating the expression and function of variety of cell membrane receptors. Before that, Dr. Rotem-Yehudar was a member of the biotechnology core team of Compugen. Prior thereto, she was a post-doctoral fellow at the laboratory of Prof. Nathan Nelson at Tel-Aviv University, Israel, where she studied the molecular aspects pertaining to the function of the neurotransmitter transporter NTT4. Dr. Rotem-Yehudar holds a PhD and MSc degrees in immunology from Tel Aviv University, Israel.

Moti Hacham, LLB, Vice President Finance
Mr. Hacham who has recently joined CureTech to act as its CFO (part time) has versatile financial and legal experience. Prior to joining CureTech, Mr. Hacham has been an attorney in Ben-Shahar, Lekner & Co., one of Israel’s leading commercial law firms specializing in business and financing transactions as well as in general corporate matters of private and public biotechnology and hi-tech companies. Prior thereto he was the assistant to the CFO of Check Point Software Technologies (NASDAQ: CHKP), the worldwide leader in securing the Internet, where he played an important role in its IPO. Prior to joining Check Point, Mr. Hacham worked as a team leader at Pioneer Financial Consultants Ltd., an investment portfolio management company. Mr. Hacham has a B.A. degree in Economics from the Tel-Aviv University, Tel-Aviv, Israel and LLB degree from the Bar-Ilan University, Ramat-Gan, Israel and is a member of the Israeli bar association.